Shelter Pharma Ltd FY26 Results

Revenue ₹73.13 crore; Net Profit ₹9.03 crore.

Reader Takeaway: Strong revenue and profit growth offset by negative operating cash flow concerns.

What just happened

Shelter Pharma Ltd has released its financial results for the fiscal year ended March 31, 2026. The company reported a significant increase in both its top line and bottom line.

Revenue from operations surged by 50% to ₹73.13 crore from ₹50.66 crore in the previous fiscal year (FY25). Net profit also saw a healthy increase of 25%, rising to ₹9.03 crore from ₹7.24 crore in FY25.
The company also announced the appointment of CA Ismail Ibrahimbhai Lakhani as its Internal Auditor for FY 2026-27.

Why this matters

The double-digit growth in revenue and profit indicates positive business momentum for Shelter Pharma. The successful utilization of raised funds for working capital, reported as fully utilized with no deviation, suggests efficient deployment of capital for operational needs.

However, a key concern for investors is the negative operating cash flow of ₹-12.48 crore for FY26, contrasting with the reported net profit. This suggests that the company's earnings are not currently translating into cash generation from its core operations, which could signal potential issues with working capital management.

The backstory

Shelter Pharma operates in the pharmaceutical sector. The company had previously raised funds specifically for working capital requirements. The latest filing confirms the full utilization of these funds.

What changes now

Investors will be closely monitoring the company's ability to improve its operating cash flow in the upcoming quarters. While growth is positive, sustainable cash generation is crucial for long-term financial health and dividend capacity.

Risks to watch

The primary risk highlighted is the negative operating cash flow, which might indicate challenges in receivables collection, inventory management, or other working capital inefficiencies. Investors should watch for signs of improvement in this metric.

Peer comparison

Information not available in the filing.

Context metrics (time-bound)

• Revenue Growth (FY26 vs FY25): 50% increase from ₹50.66 crore to ₹73.13 crore.
• Profit Growth (FY26 vs FY25): 25% increase from ₹7.24 crore to ₹9.03 crore.
• Operating Cash Flow (FY26): ₹-12.48 crore.
• Basic EPS (FY26): ₹6.57 (up from ₹6.26 in FY25).

What to track next

Investors should track the company's next quarterly results, focusing on the trend of operating cash flow and its ability to convert profits into cash. Management commentary on working capital improvements will be crucial.